{
  "drug_name": "Ceftaroline",
  "tradename": "Teflaro, Zinforo",
  "usage_and_dosing": {
    "general": [
      "Ceftaroline is a parenteral advanced-generation cephalosporin with avid binding to penicillin binding protein (PBP) 2a. Hence, Ceftaroline is active against MRSA and MRSE. Activity against enterococci is poor to moderate.",
      "FDA approved (adults and children) for:",
      "Skin and skin structure infections due to certain susceptible gram-positive and gram-negative microbes, including MRSA.",
      "Community-acquired pneumonia (not MRSA).",
      "An alternative antibiotic for drug resistant genotypes.",
      "Active in vitro vs. HVISA, VISA, and VRSA.",
      "Ceftaroline is inactivated by AmpC and extended-spectrum beta-lactamases (ESBLs).",
      "Aerobic gram-negative bacilli are generally susceptible with the exception of P. aeruginosa. In vitro pattern of susceptibility of aerobic gram-negative bacilli is similar to Ceftriaxone.",
      "Protocol for Ceftaroline desensitization.",
      "For cross-allergenicity, see Drug Allergy: Penicillins, Cephalosporins, Overview.",
      "Review: Clin Infect Dis 2011;52:1156."
    ],
    "adult_dose": {
      "skin_skin_structure_infection_approved_dose": "600 mg IV (over 5-60 min) q12h x5-14 days",
      "cap_approved_dose": "600 mg IV (over 5-60 min) q12h x5-7 days",
      "other_uses_unapproved": [
          "MRSA pneumonia",
          "MRSA bacteremia",
          "MRSA endocarditis",
          "VRE endocarditis"
      ]
    },
    "pediatric_dose": {
      "age_0_to_lt_2_mon_skin_only": "6 mg/kg q8h (GA ≥34 wk, postnatal ≥12 days)",
      "age_2_mon_to_lt_2_yrs": "8 mg/kg q8h",
      "age_2_yrs_to_lt_18_yrs_le_33_kg": "12 mg/kg q8h",
      "age_ge_2_yrs_to_lt_18_yrs_gt_33_kg": "400 mg q8h or 600 mg q12h",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "2.7",
    "half_life_esrd": "No data",
    "dose_renal_function_normal": "600 mg IV q12h",
    "crcl_or_egfr": "CrCl >50: No dosage adjustment. CrCl 30-50: 400 mg q12h. CrCl 15-30: 300 mg q12h. CrCl <15: 200 mg q12h",
    "hemodialysis": "200 mg q12h",
    "capd": "No data",
    "crrt": "70 kg pt, effluent flow rate 3 L/hr: 400 mg q12h 2",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "other_adjustment": [
    "ECMO: See ECMO Drug Dosing Adjustment.",
    "Obesity: See Obesity Dosing Adjustments."
  ],
  "adverse_effects": [
    "As for all cephalosporins, there is risk of allergic reaction or development of C. difficile colitis.",
    "Positive Coomb's test in 9.8% of patients without clinical hemolysis.",
    "Nausea, diarrhea, rash developed in 2-5%.",
    "Case report of eosinophilic pneumonia (Am J Health Syst Pharm 2014;71:403).",
    "Retrospective study found reversible neutropenia in 21% of patients treated for ≥3 weeks (J Antimicrob Chemother 2016;71: 2010)."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "No data, but adverse effects not expected. Monitor infant for GI toxicity.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "21.3 (600 mg IV q12h, SS)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "20",
    "volume_of_distribution_vd_l_vss": "20.3 L (Vss)",
    "avg_serum_half_life_hr": "2.7",
    "elimination": "Renal",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "<10",
    "therapeutic_levels_in_csf": "Maybe (at high doses) 21",
    "auc_ug_hr_ml": "56.3 (600 mg q12h, 0-12h)"
  },
  "major_drug_interactions": [
    "No significant interactions."
  ]
}
